Wall Street brokerages expect that United Therapeutics Co. (NASDAQ:UTHR) will announce $3.37 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for United Therapeutics’ earnings. The lowest EPS estimate is $3.12 and the highest is $3.85. United Therapeutics posted earnings per share of $3.84 during the same quarter last year, which suggests a negative year-over-year growth rate of 12.2%. The firm is expected to issue its next quarterly earnings results on Wednesday, October 27th.
On average, analysts expect that United Therapeutics will report full year earnings of $11.07 per share for the current financial year, with EPS estimates ranging from $10.47 to $11.88. For the next financial year, analysts forecast that the firm will post earnings of $15.53 per share, with EPS estimates ranging from $11.72 to $17.94. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, August 4th. The biotechnology company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.02 by $0.63. United Therapeutics had a net margin of 29.60% and a return on equity of 13.69%. The company had revenue of $446.50 million for the quarter, compared to analyst estimates of $378.54 million. During the same quarter last year, the firm posted $3.68 earnings per share. The business’s quarterly revenue was up 23.3% on a year-over-year basis.
In other United Therapeutics news, Director Christopher Causey sold 2,610 shares of the firm’s stock in a transaction on Friday, August 6th. The stock was sold at an average price of $210.00, for a total value of $548,100.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Paul A. Mahon sold 6,000 shares of United Therapeutics stock in a transaction dated Thursday, September 2nd. The shares were sold at an average price of $210.94, for a total transaction of $1,265,640.00. Following the sale, the executive vice president now owns 42,369 shares in the company, valued at $8,937,316.86. The disclosure for this sale can be found here. In the last ninety days, insiders sold 14,610 shares of company stock valued at $3,038,220. 12.10% of the stock is currently owned by corporate insiders.
Institutional investors have recently modified their holdings of the business. Arizona State Retirement System increased its stake in United Therapeutics by 0.5% in the 1st quarter. Arizona State Retirement System now owns 12,937 shares of the biotechnology company’s stock worth $2,164,000 after purchasing an additional 58 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS grew its stake in United Therapeutics by 0.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 14,923 shares of the biotechnology company’s stock valued at $2,677,000 after acquiring an additional 63 shares in the last quarter. Rockefeller Capital Management L.P. grew its stake in United Therapeutics by 8.6% during the 1st quarter. Rockefeller Capital Management L.P. now owns 913 shares of the biotechnology company’s stock valued at $152,000 after acquiring an additional 72 shares in the last quarter. GW Henssler & Associates Ltd. grew its stake in United Therapeutics by 2.4% during the 2nd quarter. GW Henssler & Associates Ltd. now owns 3,055 shares of the biotechnology company’s stock valued at $548,000 after acquiring an additional 73 shares in the last quarter. Finally, Banque Cantonale Vaudoise grew its stake in United Therapeutics by 15.3% during the 1st quarter. Banque Cantonale Vaudoise now owns 624 shares of the biotechnology company’s stock valued at $104,000 after acquiring an additional 83 shares in the last quarter. Hedge funds and other institutional investors own 94.95% of the company’s stock.
Shares of UTHR stock traded up $4.63 during mid-day trading on Wednesday, reaching $199.73. 2,801 shares of the company were exchanged, compared to its average volume of 350,693. United Therapeutics has a fifty-two week low of $99.07 and a fifty-two week high of $216.90. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.15 and a current ratio of 7.44. The company has a market capitalization of $8.97 billion, a P/E ratio of 18.96 and a beta of 0.49. The business’s 50 day simple moving average is $200.58 and its 200 day simple moving average is $191.08.
About United Therapeutics
United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening diseases. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension and high-risk neuroblastoma.
Recommended Story: What is a trade deficit?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.